Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
IPSC Century Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: IPSC
Price (delayed)
$0.56
Market cap
$48.19M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.61
Enterprise value
$35.93M
Highlights
The revenue has surged by 195% year-on-year and by 145% since the previous quarter
Century Therapeutics's gross profit has soared by 195% YoY and by 145% from the previous quarter
The debt has grown by 4.9% year-on-year but it has declined by 3.7% since the previous quarter
The quick ratio has dropped by 85% since the previous quarter and by 85% year-on-year
The equity has declined by 18% since the previous quarter and by 13% year-on-year
Key stats
What are the main financial stats of IPSC
Market
Valuations
Earnings
Shares outstanding
86.05M
Market cap
$48.19M
Enterprise value
$35.93M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.3
Price to sales (P/S)
6.68
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.45
Revenue
$6.59M
Gross profit
$6.59M
Operating income
-$138.14M
Net income
-$126.57M
EBIT
-$124.78M
EBITDA
-$111.47M
Free cash flow
-$110.29M
Per share
Balance sheet
Liquidity
EPS
-$1.61
EPS diluted
-$1.61
Free cash flow per share
-$1.4
Book value per share
$1.9
Revenue per share
$0.08
TBVPS
$4.06
Total assets
$353.22M
Total liabilities
$191.85M
Debt
$48.96M
Equity
$161.36M
Working capital
$64.27M
Debt to equity
0.3
Current ratio
1.5
Quick ratio
1.48
Net debt/EBITDA
0.11
Margins
Efficiency
Dividend
EBITDA margin
-1,691.8%
Gross margin
100%
Net margin
-1,920.9%
Operating margin
-2,096.5%
Return on assets
-33.6%
Return on equity
-66.9%
Return on invested capital
-41.7%
Return on capital employed
-55.8%
Return on sales
-1,893.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IPSC stock price
How has the Century Therapeutics stock price performed over time
Intraday
8.23%
1 week
4.28%
1 month
12%
1 year
-82.11%
YTD
-44.55%
QTD
17.65%
Financial performance
How have Century Therapeutics's revenue and profit performed over time
Revenue
$6.59M
Gross profit
$6.59M
Operating income
-$138.14M
Net income
-$126.57M
Gross margin
100%
Net margin
-1,920.9%
The revenue has surged by 195% year-on-year and by 145% since the previous quarter
Century Therapeutics's gross profit has soared by 195% YoY and by 145% from the previous quarter
The net margin has surged by 69% year-on-year and by 60% since the previous quarter
Century Therapeutics's operating margin has surged by 68% YoY and by 61% QoQ
Price vs fundamentals
How does IPSC's price correlate with its fundamentals
Growth
What is Century Therapeutics's growth rate over time
Valuation
What is Century Therapeutics stock price valuation
P/E
N/A
P/B
0.3
P/S
6.68
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.45
The EPS has increased by 30% year-on-year and by 13% since the previous quarter
IPSC's price to book (P/B) is 67% lower than its last 4 quarters average of 0.9
The equity has declined by 18% since the previous quarter and by 13% year-on-year
The revenue has surged by 195% year-on-year and by 145% since the previous quarter
The price to sales (P/S) is 93% lower than the last 4 quarters average of 89.6
Efficiency
How efficient is Century Therapeutics business performance
The return on sales has surged by 68% year-on-year and by 61% since the previous quarter
Century Therapeutics's ROE has decreased by 14% YoY
The ROIC has contracted by 14% YoY and by 9% from the previous quarter
Century Therapeutics's return on assets has increased by 2% QoQ
Dividends
What is IPSC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IPSC.
Financial health
How did Century Therapeutics financials performed over time
Century Therapeutics's total assets is 84% higher than its total liabilities
The current ratio has plunged by 86% from the previous quarter and by 85% YoY
The quick ratio has dropped by 85% since the previous quarter and by 85% year-on-year
The debt is 70% smaller than the equity
IPSC's debt to equity is up by 20% year-on-year and by 15% since the previous quarter
The equity has declined by 18% since the previous quarter and by 13% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.